Akebia Therapeutics Ownership | Who Owns Akebia Therapeutics?
Akebia Therapeutics Ownership Summary
Akebia Therapeutics is owned by 34.84% institutional investors, 4.23% insiders, and 60.92% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 7.30% of AKBA shares. State Street® SPDR® S&P® Biotech ETF is the top mutual fund, with 3.22% of its assets in Akebia Therapeutics shares.
AKBA Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Akebia Therapeutics | 34.84% | 4.23% | 60.92% |
| Sector | Healthcare Stocks | 232.64% | 10.66% | -143.30% |
| Industry | Biotech Stocks | 382.13% | 10.41% | -292.54% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 19.32M | 7.30% | $31.10M |
| Vanguard group | 16.02M | 6.05% | $25.79M |
| Blackrock | 11.64M | 5.68% | $11.87M |
| State street | 11.84M | 4.51% | $32.34M |
| Alerce investment management | 5.75M | 2.73% | $10.92M |
| Geode capital management | 6.28M | 2.37% | $10.11M |
| Goldman sachs group | 4.71M | 1.78% | $7.58M |
| Renaissance | 3.59M | 1.36% | $5.78M |
| Qube research | 3.21M | 1.22% | $8.75M |
| Bioimpact capital | 2.89M | 1.10% | $7.89M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Alerce investment management | 5.75M | 19.23% | $10.92M |
| Bioimpact capital | 2.89M | 1.29% | $7.89M |
| Nantahala capital management | 2.00M | 0.11% | $3.22M |
| Entrypoint capital | 127.50K | 0.08% | $205.28K |
| Orchard capital management | 53.51K | 0.07% | $86.15K |
| Round rock advisors | 166.09K | 0.04% | $267.40K |
| Sherbrooke park advisers | 28.39K | 0.04% | $77.50K |
| Alphamark advisors | 38.46K | 0.03% | $73.00K |
| Unified investment management | 18.00K | 0.03% | $28.98K |
| Hennion & walsh asset management | 498.96K | 0.03% | $803.33K |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Blackrock | 11.64M | 0.00% | 9.10M |
| State street | 11.84M | 0.00% | 3.85M |
| Goldman sachs group | 4.71M | 0.00% | 2.94M |
| Invesco | 2.40M | 0.00% | 2.02M |
| Hrt financial lp | 1.62M | 0.01% | 1.59M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Morgan stanley | 1.23M | 0.00% | -3.09M |
| Aigh capital management | - | - | -2.92M |
| Ubs group | 871.53K | 0.00% | -2.77M |
| Franklin resources | 181.62K | 0.00% | -2.50M |
| Affinity asset advisors | - | - | -2.45M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Nordea investment management ab | 752.11K | 0.00% | 752.11K | $1.21M |
| Hennion & walsh asset management | 498.96K | 0.03% | 498.96K | $803.33K |
| Jump financial | 355.84K | 0.01% | 355.84K | $971.45K |
| Voleon capital management lp | 211.77K | 0.01% | 211.77K | $578.12K |
| Freestone grove partners lp | 202.12K | 0.00% | 202.12K | $551.79K |
Sold Out
| Holder | Change |
|---|---|
| Stephens consulting | -6.00 |
| Pnc financial services group | -13.00 |
| True wealth design | -58.00 |
| Capital performance advisors llp | -68.00 |
| Hexagon capital partners | -186.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 111 | -39.01% | 92,263,820 | -25.41% | 34 | 1.57% | 48 | -56.36% | 35 | -2.78% |
| Sep 30, 2025 | 172 | 12.42% | 122,932,544 | 28.32% | 46 | 2.83% | 102 | -3.77% | 34 | 54.55% |
| Jun 30, 2025 | 162 | 8.72% | 108,281,334 | 13.45% | 45 | 2.80% | 111 | 19.35% | 23 | -11.54% |
| Mar 31, 2025 | 150 | 19.05% | 95,500,610 | 40.77% | 40 | 3.90% | 94 | 34.29% | 27 | 22.73% |
| Dec 31, 2024 | 124 | 4.20% | 67,787,367 | 14.05% | 32 | 4.04% | 70 | 18.64% | 22 | -15.38% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 8.55M | 3.22% | -46.02K |
| Vanguard Total Stock Mkt Idx Inv | 7.91M | 2.98% | - |
| Vanguard US Total Market Shares ETF | 5.95M | 2.52% | - |
| iShares Russell 2000 ETF | 6.27M | 2.36% | 6.27M |
| SPDR® S&P Biotech ETF | 3.09M | 1.17% | 6.91K |
| Vanguard Institutional Extnd Mkt Idx Tr | 2.90M | 1.09% | 15.52K |
| Fidelity Small Cap Index | 2.51M | 0.94% | -2.98K |
| iShares Russell 2000 Value ETF | 1.97M | 0.74% | 1.97M |
| Foord Global Equity (Lux) A | 1.96M | 0.74% | 1.96M |
| Foord Global Equity Class B | 1.83M | 0.69% | 1.83M |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 04, 2026 | Butler John P. | CEO and President | Buy | $86.59K |
| Feb 02, 2026 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | $50.24K |
| Feb 02, 2026 | Malabre Richard C | SVP, Chief Accounting Officer | Sell | $18.60K |
| Feb 02, 2026 | Grund Nicholas | Chief Commercial Officer | Sell | $43.43K |
| Feb 02, 2026 | Grund Nicholas | Chief Commercial Officer | Sell | $74.48K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | 1 | 15 |
| 2025 Q2 | - | 3 |
| 2025 Q1 | - | 8 |
| 2024 Q2 | - | 2 |
| 2024 Q1 | - | 10 |
AKBA Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools